Scientific intelligence record
Experience 2.0
Growth hormone secretagogue peptide
Synthetic growth-hormone secretagogue and ghrelin-receptor agonist studied in endocrine challenge testing.
Record status
Traceability partial
Last meaningful update: 9/20/2026
Ranked research corpus
269
Categorized publications with transparent machine-proposed ranking; human appraisal pending.
global evidence atlas
This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.
269 matching records · ranked 2026-09-18
Page 1 of 11
Europe PMC · 2026 · PMID 42732957 · DOI 10.1507/endocrj.ej26-0192
human-observational
Europe PMC · 2026 · PMID 42395176 · DOI 10.3389/fendo.2026.1822475
human-interventional
Europe PMC · 2025 · PMID 40277822 · DOI 10.3390/diseases13040112
human-observational
Europe PMC · 2025 · PMID 39672241 · DOI 10.1016/j.arthro.2024.11.094
preclinical-animal
Europe PMC · 2025 · PMID 40677481 · DOI 10.7759/cureus.86185
human-observational
Europe PMC · 2023 · PMID 37295337 · DOI 10.1016/j.ghir.2023.101545
preclinical-animal
WPF seed · 2022 · PMID 35452483 · DOI 10.1210/jcem.77.3.8103770
laboratory-mechanistic
Europe PMC · 2022 · PMID 35452483 · DOI 10.1371/journal.pone.0267324
human-observational
OpenAlex · 2022 · Source ID doi:10.1507/endocrine.98.s.hpt_47 · DOI 10.1507/endocrine.98.s.hpt_47
preclinical-animal
Europe PMC · 2022 · Source ID pmcid:pmc9626921
human-observational
Europe PMC · 2022 · PMID 35758863 · DOI 10.1080/15360288.2022.2063469
preclinical-animal
OpenAlex · 2021 · Source ID openalex:w7146705845
contextual-unclassified
Europe PMC · 2021 · Source ID pmcid:pmc8090618
human-observational
Europe PMC · 2021 · PMID 33197153 · DOI 10.1002/dta.2975
preclinical-animal
Europe PMC · 2021 · PMID 34090190 · DOI 10.1016/j.ijscr.2021.106023
human-observational
WPF seed · 2020 · PMID 32652605 · DOI 10.1002/bmc.4948
laboratory-mechanistic
Europe PMC · 2020 · PMID 32300840 · DOI 10.1007/s00216-020-02634-4
preclinical-animal
Europe PMC · 2020 · Source ID pmcid:pmc7212462
human-observational
Europe PMC · 2020 · PMID 31776295 · DOI 10.1507/endocrj.ej19-0288
human-observational
WPF seed · 2019 · PMID 31758732 · DOI 10.1002/dta.2741
laboratory-mechanistic
OpenAlex · 2019 · Source ID openalex:w2995043760
contextual-unclassified
WPF seed · 2019 · PMID 30136411 · DOI 10.1002/dta.2489
laboratory-mechanistic
Europe PMC · 2019 · PMID 30051972 · DOI 10.1002/dta.2467
contextual-unclassified
OpenAlex · 2019 · Source ID openalex:w2992948133
contextual-unclassified
OpenAlex · 2019 · Source ID openalex:w2992821544
contextual-unclassified
governance and regulatory context
No new outcome conclusion is inferred from discovery metadata. Named accountable approval is required for governed scientific conclusions.
Absence of a record in this pass is not proof that no authorization exists. Status must remain jurisdiction-, product-, formulation-, and date-specific.
No machine-proposed evidence-strength grades exist yet for this compound; all screening records are unassigned pending further review. 2 correction(s) have been recorded against this atlas's source metadata.
GHRP-2 evidence · ranking key
A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.
Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.
Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.
Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.
Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.
peptide explorer
Evidence-class labeling remains visible even when interactive rendering is unavailable. Representative geometry is not an experimentally determined or predicted biological conformation.
Fully specified molecular identity
Non-standard residues and stereochemistry are exact in notation, not inferred from the viewer.
Sources: NIH PubChem — Pralmorelin / GHRP-2 · reviewed 2026-09-17
APA
World Peptide Foundation. (n.d.). GHRP-2 — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 20, 2026.) https://www.worldpeptidefoundation.org/directory/ghrp-2
AMA / Vancouver
World Peptide Foundation. GHRP-2 — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 20, 2026. https://www.worldpeptidefoundation.org/directory/ghrp-2
Featured tiered studies
0
Cornerstone publications with study-level interpretation, limitations, and tier disclosure.
Research domains
6
Clinical and scientific questions synthesized independently across the evidence atlas.
Governed reviewed evidence
25
Database records promoted through the governed publication workflow—not the corpus total.
Corpus generated 2026-09-18. Counts remain separately labeled to prevent automated screening from being represented as completed human review.
Human experience · separate evidence stream
Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.
Observation is valuable human context. It is not evidence of causation, efficacy, or safety.
Public display gate
n ≥ 20 eligible observations
Exact progress remains private before the threshold.
Intelligence snapshot
A compact view of what is represented, what remains unresolved, and how completely the record can be traced.
Ranked research corpus
269
Categorized screening records; proposed rankings remain pending human appraisal.
Featured tiered studies
0
Cornerstone studies with published study-level interpretation and tier disclosure.
Research domains
6
Independent evidence dossiers covering the major research questions.
Governed reviewed evidence
25
Reviewed database records promoted through the governed publication workflow.
Contradictions
0
Conflicting evidence relationships that remain visible.
Research gaps
1
Questions the current record identifies as unresolved.
Connected media
0
Media records explicitly linked to this scientific record.
What we know
The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.
Reconciled domain conclusions
GHRP-2 no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded conclusion, confidence level, evidence synthesis, limitations, geographic applicability, regulatory interpretation, and research gaps.
Inspect the reconciled evidence atlasPubMed-indexed controlled clinical trial; journal article; research support, non-u.s. gov't; validation study examining a simple diagnostic test using gh-releasing peptide-2 in adult gh deficiency. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed clinical trial; comparative study; journal article; randomized controlled trial; research support, non-u.s. gov't examining pituitary responsiveness to gh-releasing hormone, gh-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness. Machine-staged source candidate; findings and limitations require accountable review before publication.
Scientific context
Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.
Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.
Explore further
Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.
Research
Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.
1993 · study · Temporal status not established
The Journal of pediatric endocrinology
1996 · study · Temporal status not established
Clinical endocrinology
1997 · study · Temporal status not established
European journal of endocrinology
1998 · study · Temporal status not established
European journal of endocrinology
2000 · study · Temporal status not established
The Journal of endocrinology
2004 · study · Temporal status not established
Drugs in R&D
2004 · study · Temporal status not established
Arzneimittel-Forschung
2004 · study · Temporal status not established
Arzneimittel-Forschung
2005 · study · Temporal status not established
The Journal of clinical endocrinology and metabolism
2005 · study · Temporal status not established
Naunyn-Schmiedeberg's archives of pharmacology
2006 · study · Temporal status not established
Naunyn-Schmiedeberg's archives of pharmacology
2007 · study · Temporal status not established
European journal of endocrinology
2009 · study · Temporal status not established
Regulatory peptides
2012 · study · Temporal status not established
Analytical chemistry
2014 · study · Temporal status not established
BioMed research international
2015 · study · Temporal status not established
AAPS PharmSciTech
2016 · study · Temporal status not established
International journal of molecular sciences
2017 · study · Temporal status not established
Drug testing and analysis
2017 · study · Temporal status not established
American journal of men's health
2018 · study · Temporal status not established
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
2018 · study · Temporal status not established
Endocrine journal
2019 · study · Temporal status not established
Drug testing and analysis
2019 · study · Temporal status not established
Drug testing and analysis
2020 · study · Temporal status not established
Biomedical chromatography : BMC
2022 · study · Temporal status not established
PloS one
2026 · regulatory · Temporal status not established
European Union
2026 · regulatory · Temporal status not established
United States
The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.
No institutional claim record is currently represented for this peptide.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.
3 represented evidence records
Years represented: 2012, 2018, 2019
Publishing organizations appearing in records: Analytical chemistry, Drug testing and analysis, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
2 represented evidence records
Years represented: 2012, 2018
Publishing organizations appearing in records: Analytical chemistry, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
2 represented evidence records
Years represented: 1993, 1996
Publishing organizations appearing in records: Clinical endocrinology, The Journal of pediatric endocrinology
2 represented evidence records
Years represented: 2004, 2005
Publishing organizations appearing in records: Arzneimittel-Forschung, Naunyn-Schmiedeberg's archives of pharmacology
2 represented evidence records
Connections
Connections appear only when they are represented by the project’s underlying records.
institution
institution
institution
institution
institution
institution
institution
institution
institution
institution
institution
institution
Traceability
The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.
Source publication state
A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.
Reviewer provenance state
“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.
Domain conclusion → Evidence
Connected
Evidence → Source
Connected
Source → Original record
Connected
Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.
Reconciled for 6 domain conclusions and 0 featured studies.
Detailed study-to-domain mappings and original-source paths appear in the GHRP-2 evidence-governance section.
Inspect the ranked source recordsObservational archive
Observational archive data is intentionally separated from published scientific evidence.
Observational boundary
Insufficient eligible observations are available for display under the current filters.
Insufficient eligible observations are currently represented to display aggregated findings for this peptide.
Regulatory context
Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.
European Union
Regulator: Not represented
As of: 9/9/2026 · Temporal status not established
Regulatory context incomplete: regulator.
United States
Regulator: Not represented
As of: 9/9/2026 · Temporal status not established
Regulatory context incomplete: regulator.
Research + media
Only media explicitly linked through the project’s relationship system appears here.
No scientifically connected media is currently represented for this peptide.
Sources + provenance
Generated: 9/24/2026, 3:25:16 AM
Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.
Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.
This is a representative, sequence-derived model ordered by residue position only. It is not the peptide's experimentally determined or predicted biological conformation, and it carries no claim about real bond angles, distances, secondary structure, binding sites, or activity.
PubMed-indexed journal article; review examining pralmorelin: ghrp 2, gpa 748, growth hormone-releasing peptide 2, kp-102 d, kp-102 ln, kp-102d, kp-102ln. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining pharmacological characteristics of kp-102 (ghrp-2), a potent growth hormone-releasing peptide. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed comparative study; journal article; research support, u.s. gov't, p.h.s. examining gh releasing peptides--structure and kinetics. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining glycine-modified growth hormone secretagogues identified in seized doping material. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, non-u.s. gov't examining analysis of new growth promoting black market products. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining evaluation of growth hormone-releasing peptide-2 for diagnosis of thyrotropin-producing pituitary adenomas. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining detection of black market follistatin 344. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, u.s. gov't, p.h.s. examining growth hormone releasing peptide-2 (ghrp-2), like ghrelin, increases food intake in healthy men. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, non-u.s. gov't; review examining growth hormone-releasing peptides. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s. examining the hexapeptide kp-102 (d-ala-d-beta-nal-ala-trp-d-phe-lys-nh(2)) stimulates growth hormone release in a cichlid fish (ooreochromis mossambicus). Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, non-u.s. gov't examining intraportal infusion of ghrelin could inhibit glucose-stimulated glp-1 secretion by enteric neural net in wistar rat. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining ipamorelin, the first selective growth hormone secretagogue. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, non-u.s. gov't examining association between overweight and growth hormone secretion in patients with non-functioning pituitary tumors. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining structure-activity relationship for peptídic growth hormone secretagogues. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining synthesis of mono-pegylated growth hormone releasing peptide-2 and investigation of its biological activity. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining determination of the immunostimulatory drug-glucosoaminyl-muramyl-dipeptide-in human plasma using hplc-ms/ms and its application to a pharmacokinetic study. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining general pharmacology of kp-102 (ghrp-2), a potent growth hormone-releasing peptide. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, non-u.s. gov't examining metabolism of growth hormone releasing peptides. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining growth hormone secretagogue treatment in hypogonadal men raises serum insulin-like growth factor-1 levels. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining kp-102 (growth hormone-releasing peptide-2) attenuates ischemia/reperfusion injury in isolated rat hearts. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, non-u.s. gov't examining growth hormone-releasing peptide-2 stimulates secretion and synthesis of adrenocorticotropic hormone in mouse pituitary. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining acth releasing activity of kp-102 (ghrp-2) in rats is mediated mainly by release of crf. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining growth hormone releasing peptide-2 attenuation of protein kinase c-induced inflammation in human ovarian granulosa cells. Machine-staged source candidate; findings and limitations require accountable review before publication.
Years represented: 2004, 2005
Publishing organizations appearing in records: Arzneimittel-Forschung, Naunyn-Schmiedeberg's archives of pharmacology
2 represented evidence records
Years represented: 2009, 2018
Publishing organizations appearing in records: Endocrine journal, Regulatory peptides
2 represented evidence records
Years represented: 2004, 2007
Publishing organizations appearing in records: Arzneimittel-Forschung, European journal of endocrinology
3 represented evidence records
Years represented: 2004, 2005
Publishing organizations appearing in records: Arzneimittel-Forschung, Naunyn-Schmiedeberg's archives of pharmacology
3 represented evidence records
Years represented: 2004, 2005
Publishing organizations appearing in records: Arzneimittel-Forschung, Naunyn-Schmiedeberg's archives of pharmacology
2 represented evidence records
Years represented: 2012, 2018
Publishing organizations appearing in records: Analytical chemistry, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
2 represented evidence records
Years represented: 2004, 2006
Publishing organizations appearing in records: Arzneimittel-Forschung, Naunyn-Schmiedeberg's archives of pharmacology
2 represented evidence records
Years represented: 2009, 2018
Publishing organizations appearing in records: Endocrine journal, Regulatory peptides